{"nctId":"NCT01474538","briefTitle":"Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy","startDateStruct":{"date":"2011-12"},"conditions":["Type 2 Diabetes Mellitus"],"count":122,"armGroups":[{"label":"Insulin Lispro, then Insulin Aspart","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin Lispro"]},{"label":"Insulin Aspart, then Insulin Lispro","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin Aspart"]}],"interventions":[{"name":"Insulin Lispro","otherNames":["Humalog","LY275585"]},{"name":"Insulin Aspart","otherNames":["Novolog"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have type 2 diabetes (per World Health Organization \\[WHO\\] Classification of Diabetes)\n* Have been treated with CSII therapy using a rapid-acting analog for the previous 6 months\n* Have a screening A1C less than or equal to 9.0% (no lower limit for A1C)\n* Have a body mass index (BMI) less than 45 kilograms/square meter (kg/m²) at screening\n* Have a history of stable body weight (not varying by greater than 10% for at least 3 months prior to screening)\n* For participants on oral anti-diabetes medications (OAMs): must have been on a stable dose of OAMs, labeled for use with insulin, for at least 3 months prior to study entry\n\nExclusion Criteria:\n\n* Have severe insulin resistance \\[require greater than 2 units/kilogram/day (U/kg/day) of insulin\\]\n* Are taking or have taken within the last 3 months, antihyperglycemic medication not approved for use with insulin, injectable non-insulin antihyperglycemic medications, or have a contraindication to current antihyperglycemic medication\n* Have a serum creatinine greater than or equal to 2 milligrams/deciliter (mg/dL) if not on metformin; known metabolic or lactic acidosis; any condition associated with hypoperfusion, hypoxemia, dehydration, or sepsis; and/or a radiologic contrast study within 48 hours prior to study entry\n* Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical, intraocular, intraarticular, and inhaled preparations) or have received such therapy within 2 weeks immediately before screening\n* Have had more than 1 episode of hypoglycemia (defined as requiring assistance of a third party due to disabling hypoglycemia) within 6 months prior to entry into the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Glycosylated Hemoglobin A1C (HbA1c) at Endpoint","description":"Hemoglobin A1c (HbA1c) is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over the last 8-12 weeks. Least Squares (LS) means were adjusted for treatment, period, sequence, thiazolidinedione use (Yes/No), baseline HbA1c (\\>8% or ≤8%) and participants.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.50","spread":"0.12"},{"groupId":"OG001","value":"7.40","spread":"0.12"}]}]}]},{"type":"SECONDARY","title":"Total Daily Insulin Dose","description":"Total daily insulin dose was the average of the last 3 days total insulin dose immediately prior to the Week 16 (endpoint) visit of each treatment period. Least Squares (LS) means were adjusted for treatment, period, sequence, thiazolidinedione use (Yes/No), baseline Hemoglobin A1c (HbA1c) (\\>8% or ≤8%) and participants.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.41","spread":"4.78"},{"groupId":"OG001","value":"80.69","spread":"4.77"}]}]}]},{"type":"SECONDARY","title":"Rate of Hypoglycemic Events Per 30 Days","description":"A hypoglycemic episode is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has blood glucose concentration of ≤70 milligrams/deciliter \\[mg/dL (3.9 millimoles/liter (mmol/L)\\]. Least Squares (LS) means were adjusted for treatment, period, sequence, baseline hypoglycemic event rate, thiazolidinedione use (Yes/No) and baseline Hemoglobin A1c (HbA1c) (\\>8% or ≤8%).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.24","spread":"0.28"},{"groupId":"OG001","value":"2.38","spread":"0.29"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Weight","description":"Least Squares (LS) means were adjusted for treatment, period, sequence, thiazolidinedione use (Yes/No), baseline Hemoglobin A1c (HbA1c) (\\>8% or ≤8%), baseline weight and participants.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"0.53"},{"groupId":"OG001","value":"0.89","spread":"0.52"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hypoglycemic Events","description":"A hypoglycemic episode is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has blood glucose concentration of ≤ 70 milligrams/deciliter \\[mg/dL (3.9 millimoles/liter (mmol/L)\\]. The percentage of participants is the total number of participants experiencing hypoglycemic events divided by number of participants in the treatment arm multiplied by 100.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2","spread":null},{"groupId":"OG001","value":"74.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":118},"commonTop":["Nasopharyngitis","Fatigue","Nausea","Sinusitis","Back pain"]}}}